RT Journal Article
SR Electronic
T1 Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20067066
DO 10.1101/2020.04.15.20067066
A1 Daniel B. Larremore
A1 Bailey K. Fosdick
A1 Kate M. Bubar
A1 Sam Zhang
A1 Stephen M. Kissler
A1 C. Jessica E. Metcalf
A1 Caroline O. Buckee
A1 Yonatan H. Grad
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.04.15.20067066.abstract
AB Establishing how many people have already been infected by SARS-CoV-2 is an urgent priority for controlling the COVID-19 pandemic. Patchy virological testing has hampered interpretation of confirmed case counts, and unknown rates of asymptomatic and mild infections make it challenging to develop evidence-based public health policies. Serological tests that identify past infection can be used to estimate cumulative incidence, but the relative accuracy and robustness of various sampling strategies has been unclear. Here, we used a flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across tested subpopulations to compare estimates from sampling schemes. Using the same framework and making the assumption that serological positivity indicates immune protection, we propagated these estimates and uncertainty through dynamical models to assess the uncertainty in the epidemiological parameters needed to evaluate public health interventions. We examined the relative accuracy of convenience samples versus structured surveys to estimate population seroprevalence and found that sampling schemes informed by demographics and contact networks outperform uniform sampling. The framework can be adapted to optimize the design of serological surveys given particular test characteristics and capacity, population demography, sampling strategy, and modeling approach, and can be tailored to support decision-making around introducing or removing interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported in part by the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and open-source code for this manuscript can be found in the github repository referenced in this paper. https://github.com/LarremoreLab/covid_serological_sampling